UPDATE: C.K. Cooper Initiates Coverage on DUSA Pharmaceuticals

According to a research report published earlier today, C.K. Cooper has initiated coverage on DUSA Pharmaceuticals Inc.

with a Buy rating and $8 PT. In the report, C.K. Cooper commented, “We expect a blow-out fourth quarter benefiting from strong seasonal demand combined with stocking orders resulting from the announced price increase during the fourth quarter, which took effect Jan. 1, 2012. This should contribute to a very strong finish to what we expect to be the second full year of profitability of Dusa.” Dusa Pharmaceuticals closed yesterday at $4.65.